List of Excipients in Branded Drug JANTOVEN

Generic Drugs Containing JANTOVEN

Company	Ingredient	NDC	Excipient
Upsher-Smith Laboratories LLC	warfarin sodium	0832-1211	FD&C RED NO. 40
Upsher-Smith Laboratories LLC	warfarin sodium	0832-1211	LACTOSE MONOHYDRATE
Upsher-Smith Laboratories LLC	warfarin sodium	0832-1211	MAGNESIUM STEARATE
Upsher-Smith Laboratories LLC	warfarin sodium	0832-1211	POVIDONE

What are the Most Frequently-Used Excipients in JANTOVEN?

# Of NDCs	Excipient
1	FD&C RED NO. 40
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	POVIDONE

Jantoven Excipient Strategy, Formulation IP, and Commercial Opportunities

Last updated: August 16, 2026

Jantoven is an oral warfarin sodium tablet marketed for prevention and treatment of thromboembolic events. Its active ingredient is off-patent, and commercial differentiation depends primarily on supply reliability, dose accuracy, tablet presentation, excipient control, patient adherence, and anticoagulation-service integration. The strongest opportunities are in excipient qualification, low-variability manufacturing, color and strength differentiation, packaging, and alternative warfarin dosage forms rather than in conventional composition-of-matter patents.

What is Jantoven and which excipients does it contain?

Jantoven contains warfarin sodium, a vitamin K antagonist supplied in multiple tablet strengths. FDA labeling identifies inactive ingredients that include lactose monohydrate, pregelatinized starch, crospovidone, magnesium stearate, and strength-specific colorants.[1]

The formulation is an immediate-release compressed tablet. Its commercial design relies on rapid disintegration, consistent dissolution, tablet hardness, score-line performance, and visual differentiation across strengths.

Jantoven dosage strengths and formulation design

Jantoven is marketed in the following strengths:

Strength	Dosage form	Core formulation characteristics	Commercial function
1 mg	Scored tablet	Lactose-based tablet with starch, crospovidone, lubricant and colorant	Low-dose initiation and maintenance
2 mg	Scored tablet	Same excipient platform with strength-specific color	Maintenance dosing
2.5 mg	Scored tablet	Same core platform with color differentiation	Common maintenance strength
3 mg	Scored tablet	Same core platform with color differentiation	Dose titration
4 mg	Scored tablet	Same core platform with color differentiation	Maintenance and titration
5 mg	Scored tablet	Same core platform with color differentiation	Common maintenance strength
6 mg	Scored tablet	Same core platform with color differentiation	Dose adjustment
7.5 mg	Scored tablet	Same core platform with color differentiation	Dose adjustment
10 mg	Scored tablet	Same core platform with color differentiation	Higher-dose maintenance

The exact colorant composition is strength-specific and should be controlled against the current FDA-approved prescribing information and product-specific manufacturing documentation.[1]

What does each Jantoven excipient do?

Lactose monohydrate is a diluent that contributes bulk and supports tablet compression. It also creates a potential issue for patients with lactose intolerance, although the amount in a tablet is generally small.

Preg gelatinized starch supports compression and can assist tablet disintegration. Crospovidone is a superdisintegrant that promotes tablet breakup after ingestion. Magnesium stearate acts as a lubricant during manufacture but requires control because excessive lubrication can impair tablet wettability and dissolution.

Colorants are commercially important in warfarin products. Patients, pharmacists and clinicians often identify strengths by tablet color. A change in color, shape or scoring can increase medication-error risk, particularly during dose titration.

What excipient strategy is most suitable for Jantoven?

The optimal strategy is a controlled, low-complexity immediate-release platform that preserves the established tablet profile while improving supply resilience and dose-identification safety.

Excipient priorities

Excipient or material	Strategic priority	Main risk	Commercial opportunity
Lactose monohydrate	High	Supplier variation, lactose sensitivity, moisture effects	Dual-source qualification or lactose-free reformulation
Pregelatinized starch	High	Variability in compressibility and moisture	Controlled-function grades and second-source supply
Crospovidone	High	Particle-size and disintegration variability	Premium low-variability grades
Magnesium stearate	Medium	Over-lubrication and dissolution impact	Optimized grades and process-control packages
Colorants	High	Strength confusion and regulatory change	Stable, compliant color systems
Packaging materials	High	Medication errors and moisture exposure	Unit-dose, calendar and adherence packaging
Tablet coating materials	Medium	Added process complexity	Film-coating systems that preserve visual identification

A reformulation should avoid unnecessary changes to tablet appearance, scoreability, dissolution and dose recognition. Warfarin has a narrow therapeutic index, and small changes in exposure can affect anticoagulation control. FDA guidance identifies narrow therapeutic index drugs as requiring close attention to bioequivalence and product performance.[2]

Should Jantoven move to a lactose-free formulation?

A lactose-free version could create a limited but identifiable niche. The opportunity is stronger in hospital formularies, long-term-care settings and patients who report excipient intolerance than in the broad retail market.

Potential replacement fillers include microcrystalline cellulose, mannitol or dibasic calcium phosphate. Each option changes tablet density, compression behavior, mouthfeel, moisture response and dissolution. A lactose-free platform would require comparative stability, dissolution and bioequivalence work. It would also need careful assessment of tablet weight and appearance because pharmacists commonly distinguish warfarin strengths visually.

The commercial case is strongest if the product is positioned as an excipient-controlled or intolerance-oriented alternative rather than as a general replacement for conventional warfarin tablets.

What patents protect Jantoven and its excipient formulation?

Jantoven does not have the type of active-ingredient patent estate associated with a newly approved medicine. Warfarin was discovered and commercialized decades ago. Standard generic warfarin tablets are generally exposed to competition based on abbreviated new drug applications rather than protected by current composition-of-matter patents.

The principal protection opportunities are formulation-specific and process-specific:

• A novel excipient combination that changes dissolution or stability.
• A dosage form that improves dose flexibility without increasing medication-error risk.
• A unit-dose or adherence package integrated with anticoagulation management.
• A modified-release formulation, if clinically justified.
• A low-dose pediatric formulation.
• A manufacturing process that reduces content uniformity or potency variation.
• A color, shape or score-line system with measurable safety benefits.

A conventional tablet containing warfarin sodium, lactose, starch, crospovidone and magnesium stearate would have limited patentability unless it produces an unexpected technical result. Routine substitution of one filler or lubricant for another is vulnerable to obviousness challenges under U.S. patent law.

Are Jantoven patents listed in the Orange Book?

The Orange Book is primarily relevant to approved drug products with listed patents and regulatory exclusivity. Warfarin sodium tablets are established products, and the commercial exposure for Jantoven is primarily generic competition rather than an active patent barrier.

A definitive Orange Book analysis must be performed against the current FDA publication and the specific Jantoven application number. The relevant diligence questions are whether any patent is listed, whether the patent claims the formulation or method of use, and whether any pediatric or regulatory exclusivity remains.[3]

When does Jantoven lose exclusivity?

Jantoven has no meaningful new-drug exclusivity period comparable to a recently approved branded anticoagulant. Warfarin sodium has long been available in generic form. Any commercial exclusivity that might arise from a later reformulation, new indication or drug-delivery system would depend on the specific FDA approval pathway and patent claims.

What generic entry risks exist for Jantoven?

Generic entry risk is high because:

1. Warfarin sodium is an established active ingredient.
2. Multiple manufacturers have supplied warfarin tablets.
3. The dosage form is a conventional immediate-release tablet.
4. No biologic manufacturing barrier exists.
5. Clinical substitution is familiar to pharmacists and prescribers.
6. The product does not depend on a complex device or delivery system.

The main barriers are regulatory and operational. Applicants must demonstrate pharmaceutical equivalence, bioequivalence, potency, content uniformity, dissolution and stability. Warfarin's narrow therapeutic index increases the importance of comparative exposure and product consistency.

Are there Paragraph IV challenges involving Jantoven?

Paragraph IV litigation is generally associated with a generic applicant certifying that a listed patent is invalid, unenforceable or not infringed. For an old warfarin tablet product, the more relevant risk is routine ANDA competition rather than a major current Paragraph IV campaign against a foundational Jantoven patent.

Potential litigation could arise if a sponsor obtains later patents covering a differentiated formulation, packaging system or method of use. Those patents would need to claim more than the known warfarin tablet composition to create a durable litigation position.

The commercial significance of a Paragraph IV filing would depend on the patent's scope, Orange Book listing date, 30-month stay eligibility, settlement terms and whether the generic applicant could launch at risk.

What formulation patents could create commercial value?

Low-dose and pediatric warfarin formulations

Pediatric anticoagulation is a potential niche. Smaller-dose tablets, oral granules, dispersible tablets or calibrated liquid formulations could improve dose flexibility. The formulation must control dose uniformity because pediatric dosing is often weight-based and adjusted according to INR results.

A pediatric product could support method-of-use claims if paired with a defined dosing protocol, but clinical and regulatory requirements would be higher than for a conventional adult tablet.

Unit-dose and adherence packaging

Packaging is one of the more practical opportunities. Warfarin regimens often require alternating daily doses, tablet splitting or frequent dose changes. A calendar pack or dose-specific blister system could reduce errors and improve adherence.

Potential claims could cover:

• A strength-specific daily dosing calendar.
• A package containing multiple warfarin strengths.
• Dose-change instructions linked to INR monitoring.
• Tamper-evident and moisture-protective packaging.
• Hospital or long-term-care unit-dose formats.

Packaging patents may be easier to design around than formulation patents, so commercial value would depend on integration with pharmacy workflow and anticoagulation software.

Reduced-error tablet architecture

A tablet platform with a distinct shape, color coding, tactile marking or improved score-line could address medication errors. The challenge is balancing differentiation with FDA labeling and post-approval change requirements.

An improved score line could have commercial value if it demonstrates more consistent split-tablet weight and potency. A claim directed only to a conventional score line would face substantial prior-art exposure.

What regulatory status does Jantoven have?

Jantoven is an FDA-approved prescription product containing warfarin sodium.[1] It is not a biologic and is not subject to biosimilar competition. The principal regulatory pathway for competing products is the ANDA pathway for generic drugs.

Does Jantoven face biosimilar risk?

No. Biosimilar regulation applies to biological products. Warfarin sodium is a small-molecule chemical drug. Competitive products are generics, not biosimilars.

What FDA changes would affect an excipient reformulation?

A material change to an approved Jantoven formulation could require a supplement to the approved application. The regulatory burden depends on the change, including:

• New or changed excipient.
• Change in excipient level.
• Change in colorant.
• Change in tablet composition.
• Change in manufacturing process.
• Change in dissolution profile.
• Change in container-closure system.

FDA's postapproval change framework distinguishes changes by their potential effect on identity, strength, quality, purity or potency.[4] A formulation change involving a critical excipient would require process validation, stability data and comparative product testing.

How strong is the Jantoven patent estate?

The patent estate is weak as a barrier to generic entry but potentially useful as a platform for incremental innovation.

Patent category	Barrier strength	Commercial assessment
Warfarin composition of matter	Very low	Historical protection has expired
Conventional immediate-release tablet	Low	Broad prior art and generic competition
Specific excipient combination	Low to medium	Requires unexpected performance benefit
Pediatric or low-dose product	Medium	More defensible if clinically differentiated
Modified-release delivery	Medium	Higher development and clinical risk
Dose-error-reduction packaging	Medium	Possible niche protection
Manufacturing process	Medium	Useful if difficult to replicate and measurable
Method of use	Low to medium	Depends on new patient population or protocol

The strongest claims would likely be narrow claims tied to measurable performance: improved content uniformity, controlled dissolution, reduced tablet-splitting variability, improved stability or a validated reduction in dosing errors.

Which companies are challenging or competing with Jantoven?

Competition comes from generic warfarin suppliers and from direct oral anticoagulants. The generic market has included manufacturers such as Teva, Mylan or Viatris, Zydus, Taro, Upsher-Smith and other approved ANDA holders over time. Product availability varies by strength, manufacturer, wholesaler inventory and contracting arrangements.

The more important commercial competitors are apixaban, rivaroxaban, dabigatran and edoxaban. These direct oral anticoagulants have reduced warfarin use in several indications because they offer fixed dosing and do not generally require routine INR monitoring. Warfarin remains important where cost, mechanical heart valves, severe renal impairment, drug interactions, or long-term clinical familiarity favor vitamin K antagonist therapy.[5]

How does Jantoven compare with direct oral anticoagulants?

Attribute	Jantoven	Direct oral anticoagulants
Active ingredient	Warfarin sodium	Apixaban, rivaroxaban, dabigatran or edoxaban
Monitoring	INR monitoring required	Routine coagulation monitoring usually not required
Dose	Individually titrated	Often fixed or weight/renal-function adjusted
Generic status	Mature generic market	Some products have moved or are moving into generic competition
Excipient opportunity	High for dose accuracy and packaging	Higher for complex delivery, formulation and device integration
Manufacturing complexity	Low to moderate	Product-specific
Patient switching	Common across manufacturers	More sensitive to clinical indication and payer coverage
Main commercial pressure	Generic price competition and DOAC substitution	Patent expiry, formulary competition and reimbursement

Jantoven's commercial position is strongest in cost-sensitive segments and indications in which warfarin remains clinically preferred or required. Its weakness is the monitoring burden and dose-management complexity.

What licensing deals could create value around Jantoven?

A licensing strategy should focus on enabling technologies rather than the legacy warfarin molecule. Relevant targets include:

• Controlled-function excipients for direct compression.
• Low-moisture or lactose-free tablet platforms.
• Child-resistant unit-dose packaging.
• Calendar blister systems.
• Digital adherence and INR-management tools.
• Pediatric liquid or dispersible dosage forms.
• Contract manufacturing capacity for low-volume strengths.
• Tablet inspection systems for color, score and imprint verification.

A formulation license would need a measurable advantage over existing generic tablets. A packaging or digital-management license may reach the market faster because it can improve use without changing the active formulation.

No material Jantoven-specific licensing premium should be assumed without evidence of protected technology, clinical differentiation or a durable commercial contract.

What is the revenue exposure for Jantoven?

Jantoven revenue is exposed to three forces:

1. Generic price erosion from multiple warfarin suppliers.
2. Volume migration to direct oral anticoagulants.
3. Supply and contracting performance across the nine tablet strengths.

Public company disclosures generally do not provide a standalone Jantoven revenue line. Product-level revenue should therefore be assessed through prescription volume, payer claims, wholesaler data, Medicaid and Medicare utilization, hospital formulary data, and manufacturer disclosures.

The most commercially important strengths are typically the commonly used maintenance doses, especially 2.5 mg, 5 mg and 7.5 mg, but demand varies by patient population and prescribing practice. A complete commercial model should separately estimate retail, hospital, long-term-care and anticoagulation-clinic demand.

What manufacturing and IP barriers affect Jantoven opportunities?

Manufacturing barriers are moderate rather than high. The product is a conventional tablet, but process control is important because the dose is titrated against INR and tablets are often split or combined.

Key manufacturing controls include:

• Uniform warfarin sodium distribution.
• Consistent granulation or direct-compression behavior.
• Tablet weight and hardness.
• Score-line performance.
• Disintegration and dissolution.
• Color uniformity across strengths.
• Potency stability.
• Prevention of cross-contamination.
• Reliable supply of approved colorants and functional excipients.

The largest IP barrier is prior art. Warfarin tablets, common excipients, color coding and conventional packaging are heavily established technologies. A new entrant should pursue narrowly targeted claims supported by comparative data rather than broad claims covering ordinary tablet manufacture.

Key Takeaways

• Jantoven is an established warfarin sodium tablet with a conventional immediate-release formulation.
• Its core excipients include lactose monohydrate, pregelatinized starch, crospovidone, magnesium stearate and strength-specific colorants.
• Conventional excipient substitution offers limited patent value unless it produces a documented technical advantage.
• The strongest commercial opportunities are lactose-free formulations, pediatric dosage forms, dose-error-reduction packaging, improved tablet splitting and supply-secure excipient platforms.
• Jantoven has high generic-entry exposure and no biosimilar risk.
• Direct oral anticoagulants are the main therapeutic competitors.
• A commercial strategy should prioritize adherence, INR management, packaging and manufacturing reliability over legacy molecule exclusivity.
• Any current Orange Book, patent, litigation or settlement conclusion must be confirmed against the FDA's current product and patent records.

FAQs

Can Jantoven be reformulated without new clinical trials?

Some excipient changes may qualify for an abbreviated postapproval pathway, but the regulatory requirements depend on the nature and scale of the change. Comparative dissolution, stability, manufacturing validation and, where necessary, bioequivalence data may be required.[4]

Is a lactose-free warfarin tablet commercially attractive?

Yes, but the opportunity is niche. The strongest customers would likely be hospitals, long-term-care providers and patients seeking excipient-controlled products. Commercial value would depend on superior tolerability positioning, supply reliability and reimbursement.

Can a Jantoven package contain multiple tablet strengths?

A multi-strength package is technically possible, but it would require careful labeling, child-resistant design, stability assessment and medication-error controls. The package should make daily dose changes clear to patients and pharmacists.

Does warfarin tablet color have patent value?

Color alone generally has limited patent strength because color coding is widely used in pharmaceutical products. A color system may have greater value when combined with tactile markings, validated error reduction, distinctive geometry or a specific packaging workflow.

What is the best investment thesis for Jantoven-related excipients?

The strongest thesis is a platform that improves supply resilience, dose accuracy or adherence across multiple warfarin manufacturers and strengths. A supplier dependent only on conventional lactose, starch or magnesium stearate would face commoditization and limited switching costs.

References

1. U.S. Food and Drug Administration. (n.d.). Jantoven: Warfarin sodium tablets prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2021). Product-specific guidance on warfarin sodium. Center for Drug Evaluation and Research.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
4. U.S. Food and Drug Administration. (2018). Changes to an approved NDA or ANDA: Guidance for industry.
5. January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Jr., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., Heidenreich, P. A., Murray, K. T., Shea, J. B., Tracy, C. M., & Yancy, C. W. (2019). 2019 AHA/ACC/HRS focused update of the 2014 guideline for the management of patients with atrial fibrillation. Circulation, 140(6), e285-e292.